Medicamen Organics IPO

NiftyTrader • June 19, 2024

Post Views: 454

The IPO for Medicamen Organics is a book-built issue amounting to Rs 10.54 crores. This offering consists solely of a fresh issue totaling 31 lakh shares.

The subscription period for the Medicamen Organics IPO starts on June 21, 2024, and ends on June 25, 2024. The share allotment is anticipated to be finalized on Wednesday, June 26, 2024, and the shares are expected to be listed on the NSE SME on Friday, June 28, 2024.

The IPO price range for Medicamen Organics is set between ₹32 and ₹34 per share. Investors must apply for a minimum of 4000 shares per lot, requiring at least ₹136,000 for a retail investment. High Net Worth Individuals (HNIs) must invest in a minimum of 2 lots, or 8,000 shares, which amounts to ₹272,000.

Medicamen Organics IPO Details

IPO Date	June 21, 2024 to June 25, 2024
Listing Date	[.]
Face Value	₹10 per shar
Price Band	₹32 to ₹34 per share
Lot Size	4000 Shares
Total Issue Size	3,100,000 shares (aggregating up to ₹10.54 Cr)
Fresh Issue	3,100,000 shares (aggregating up to ₹10.54 Cr)
Issue Type	Book Built Issue IPO
Listing At	NSE SME
Share holding pre issue	8,600,000
Share holding post issue	11,700,000
Market Maker portion	172,000 shares

Medicamen Organics IPO Lot Size

Application	Lots	Shares	Amount
Retail (Min)	1	4000	₹136,000
Retail (Max	1	4000	₹136,000
HNI (Min)	2	8000	₹272,000

Medicamen Organics IPO Objectives

The company intends to allocate the Net Proceeds from the Issue to the following purposes:

Covering the costs associated with registering products in international markets.
Updating the plant and enhancing production capacity.
Meeting the company’s working capital needs.
General corporate purposes

About Medicamen Organics Limited

Incorporated in 1995, Medicamen Organics Limited specializes in developing, manufacturing, and distributing pharmaceutical dosages, including generic forms such as tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders. The company serves both governmental bodies and private entities as a contract and third-party manufacturer.

Medicamen Organics Limited offers an extensive product range of 84 items, encompassing various drug categories such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, proton pump inhibitors, antihistamines, antihypertensive drugs, lipid preparations, antiparasitics, multivitamin preparations, multimineral, and non-steroidal anti-inflammatory drug (NSAIDs).

Medicamen Organics Limited Financial Information

Period Ended	31 Mar 2024	31 Mar 2023	31 Mar 2022	31 Mar 2021
Assets	3,858.07	3,211.98	2,707.21	2,634.37
Revenue	2,528.96	2,296.24	2,118.67	2,505.96
Profit After Tax	240.41	95.78	9.23	29.81
Net Worth	1,518.40	851.71	755.92	746.72
Reserves and Surplus	658.40	251.71	155.92	146.72
Total Borrowing	1,265.65	1,179.50	1,024.57	958.97

Medicamen Organics IPO Timeline

IPO Open Date	Friday, June 21, 2024
IPO Close Date	Tuesday, June 25, 2024
Basis of Allotment	Wednesday, June 26, 2024
Initiation of Refunds	Thursday, June 27, 2024
Credit of Shares to Demat	Thursday, June 27, 2024
Listing Date	Friday, June 28, 2024
Cut-off time for UPI mandate confirmation	5 PM on June 25, 2024

Conclusion

Medicamen Organics Limited, established in 1995, is a prominent player in the pharmaceutical industry, specializing in the development, manufacture, and distribution of a wide array of generic pharmaceutical dosages. With a comprehensive product lineup and a robust distribution network across India and several international markets, the company serves both government and private sectors. The upcoming IPO aims to support the company’s growth initiatives, including product registration in international markets, plant upgrades, increased production capacity, working capital needs, and general corporate purposes